Hosted on MSN22d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and ...
Medscape23d
Dual SGLT1/2 Inhibitor Protects Against MI and Stroke
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...
The Cardiology Advisor7d
Sotagliflozin May Reduce Myocardial Infarction, Stroke Risks in T2DM, CKD
In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.
TCTMD25d
Sotagliflozin Reduces Ischemic Risk in SCORED Analysis
Sotagliflozin, however, inhibits SGLT2 as well as gastrointestinal SGLT1; the latter effect, the study authors note, reduced carbohydrate absorption and blunts postprandial hyperglycemia, both of ...
The Telegraph1mon
Diabetes drug fights stroke: Medical researchers say Sotagliflozin can reduce heart attacks too
The drug blocks the functions of two proteins — SGLT1 and SGLT2 — that transport glucose and sodium across cell membranes and control blood sugar. Other gliflozins do not effectively block SGLT2. “Our ...